TLDR:
- Sands Capital has raised a new $555 million life science fund, bringing its total committed capital to $1.3 billion.
- The fund will focus on investing in therapeutic, diagnostic, and device companies in the life sciences sector.
Article Summary:
Sands Capital, a venture capital firm based in Arlington, Virginia, has successfully raised a new $555 million life science fund. This fund will be used to support investments in a variety of companies within the therapeutic, diagnostic, and device sectors of the life sciences industry. Sands Capital now has a total committed capital of $1.3 billion across the three life science-specific funds raised to date, with over $5 billion invested in life science and healthcare bets altogether. The firm has not disclosed specific therapeutic modalities of interest, but has mentioned a focus on “private therapeutics” among other life science companies.
In 2024, Sands Capital has already made significant investments in companies like BioAge Labs, which raised $170 million in a series D round, and Avenzo Therapeutics, which secured $150 million in a series A-1 round. Sands Capital has also been active in the medtech space, participating in fundraisings like Alamar Biosciences’ $128 million series C. The firm’s Executive Managing Partner, Ian Ratcliffe, has highlighted proteomics as a field with significant potential for disruption.
Sands Capital’s latest fundraising comes in the wake of other tech and health-focused firms fetching fresh funds, as well as the launch of new venture arms like Regeneron Ventures with a $500 million commitment. Overall, Sands Capital’s new fund will play a key role in supporting innovative companies in the life sciences industry.
